Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2024
Schedule of Pharmaceutical Benefits - 1 December 2024
1 December 2024 - The December 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 02 Nov 2024
Handok's rare blood disorder treatment Empaveli wins insurance coverage
1 November 2024 - Starting today, Handok's Empaveli (pegcetacoplan), a treatment for paroxysmal nocturnal haemoglobinuria, will be covered by Korean ...
Posted by Michael Wonder on 01 Nov 2024
Schedule of Pharmaceutical Benefits - 1 November 2024 update
1 November 2024 - The November 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Nov 2024
New Zealand Pharmaceutical Schedule - 1 November 2024
1 November 2024 - The November 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Oct 2024
Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process
21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly. ...
Posted by Michael Wonder on 11 Oct 2024
Roche Canada announces Columvi (glofitamab for injection) is publicly reimbursed in 7 provinces, including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia and Newfoundland
9 October 2024 - Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian ...
Posted by Michael Wonder on 10 Oct 2024
Pulmonary fibrosis drug Ofev nears key reimbursement decision in Korea
10 October 2024 - The Pharmaceutical Reimbursement Evaluation Committee under HIRA is reportedly set to review Ofev (nintedanib), a treatment ...
Posted by Michael Wonder on 10 Oct 2024
PHARMAC improves access to three cancer medicines
10 October 2024 - PHARMAC will improve access to three cancer medicines from 1 November 2024. ...
Posted by Michael Wonder on 09 Oct 2024
Heart attack survivors find new treatment for recurrence risk
4 October 2024 - Mike Lynch was only 12 when his mother died of cardiovascular disease, in the years following he ...
Posted by Michael Wonder on 20 Sep 2024
BioCryst and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Orladeyo (berotralstat), an oral, once daily therapy for the prevention of hereditary angioedema attacks
17 September 2024 - BioCryst Pharmaceuticals today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for oral, ...
Posted by Michael Wonder on 18 Sep 2024
Making more new cancer treatments available for New Zealanders
18 September 2024 - PHARMAC is consulting on a proposal to fund the medicine lenvatinib mesylate for three types of cancer ...
Posted by Michael Wonder on 17 Sep 2024
5,700 people to benefit from widened access to funded medicines
17 September 2024 - PHARMAC is widening access to seven medicines, benefitting an estimated 5,700 people within the first year ...
Posted by Michael Wonder on 09 Sep 2024
First cancer medicine decision following PHARMAC funding boost
9 September 2024 - PHARMAC has decided to widen access to two medicines for several types of cancer. ...
Posted by Michael Wonder on 09 Sep 2024
New and expanded PBS listings for Fabry disease and kidney cancer
9 September 2024 - Australians with Fabry disease, a rare genetic condition, and people with kidney cancer now have access ...
Posted by Michael Wonder on 04 Sep 2024
Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis
3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...